

Review

Extended-Spectrum β -Lactamases (ESBL) Producing Bacteria in Animals

Chien-Hao Tseng¹ , Chia-Wei Liu¹ and Po-Yu Liu^{1,2,3,4,5,*} 

¹ Division of Infectious Diseases, Taichung Veterans General Hospital, Taichung 40705, Taiwan; tedi3tedi3@vghtc.gov.tw (C.-H.T.); alice790305@vghtc.gov.tw (C.-W.L.)

² Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan

³ Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 40227, Taiwan

⁴ Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan

⁵ Genomic Center for Infectious Diseases, Taichung Veterans General Hospital, Taichung 40705, Taiwan

* Correspondence: pyliu@vghtc.gov.tw

Abstract: Animals have been identified as potential reservoirs and vectors of resistance genes, with studies showing that Gram-negative bacteria can acquire resistance through the horizontal transmission of resistance genes on plasmids. It is important to understand the distribution of antimicrobial-resistant bacteria and their drug-resistant genes in animals. Previous review articles mostly focused on a single bacterium or a single animal. Our objective is to compile all ESBL-producing bacteria isolated from various animals in recent years and provide a comprehensive viewpoint. Using a thorough PubMed literature search spanning from 1 January 2020 to 30 June 2022, studies exploring extended-spectrum beta-lactamase (ESBL) producing bacteria in animals were included. ESBL-producing bacteria are present in animals from various countries around the world. The most common sources of these bacteria were farm animals, and the most frequently isolated bacteria were *Escherichia coli* and *Klebsiella pneumoniae*. The most detected ESBL genes were *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}. The presence of ESBL-producing bacteria in animals highlights the importance of the One Health approach to address the issue of antibiotic resistance. Further research is needed to better understand the epidemiology and mechanisms of the spread of ESBL-producing bacteria in animal populations and their potential impact on human and animal health.

Keywords: antimicrobial-resistant bacteria; horizontal transmission; resistance genes



Citation: Tseng, C.-H.; Liu, C.-W.; Liu, P.-Y. Extended-Spectrum β -Lactamases (ESBL) Producing Bacteria in Animals. *Antibiotics* **2023**, *12*, 661. <https://doi.org/10.3390/antibiotics12040661>

Academic Editors: Jiun-Ling Wang, Jonathan Frye and Marc Maresca

Received: 25 February 2023

Revised: 22 March 2023

Accepted: 26 March 2023

Published: 28 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Antibiotics are important weapons for humans in fighting microbial infections and reducing overall mortality from infectious diseases. However, the increasing prevalence of antimicrobial-resistant bacteria (AMRs) in recent decades is a great challenge [1]. Studies suggest that animals are potential reservoirs and vectors of resistance genes [2]. Gram-negative bacteria (GNB), especially Enterobacterales strains, can acquire resistance through the plasmid-mediated horizontal transmission of resistance genes [3]. Increased use of antibiotics in livestock has been identified as a potential contributor to antimicrobial resistance in humans [4]. Therefore, it is also important to understand the distribution of antimicrobial-resistant bacteria and their drug-resistant genes in animals.

Bacteria that produce extended-spectrum β -lactamases (ESBLs) are considered one of the critical priority pathogens by the World Health Organization (WHO). ESBLs are a type of β -lactamase that can hydrolyze penicillins, first, second, and third-generation cephalosporins, and aztreonam but are unable to break down cephamycins or carbapenems [5]. The ESBL-encoding genes can be grouped into several families: *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTX-M}, etc. In the past, TEM and SHV-type ESBLs were the mainstream of ESBLs. However, CTX-M-type enzymes are much more commonly found in the ESBL type in recent research [5].

The widespread use of antibiotics is a contributing factor in the rise of antimicrobial resistance, particularly in the case of ESBL-producing bacteria. Previous studies have shown that the use of antibiotics within the past three months and monotherapy with specific drug classes (cephalosporins, tetracycline, macrolide, and cotrimoxazole) are associated with the prevalence of these bacteria [6,7]. The plasmids responsible for ESBL production often carry genes encoding resistance to other drug classes, such as aminoglycosides, trimethoprim, and fluoroquinolones [8]. This makes the treatment of infections caused by ESBL-producing bacteria more challenging, as the presence of these plasmids exacerbates the problem of antibiotic resistance and limits therapeutic options. In short, the overuse of antibiotics creates a favorable environment for the spread of plasmids responsible for ESBL production, which in turn contributes to the rise of antibiotic resistance.

Animals have been identified as potential reservoirs and vectors of resistance genes. The widespread use of antibiotics in animals has been linked to the increasing prevalence of antimicrobial-resistant bacteria in humans, highlighting the importance of understanding the distribution of antimicrobial-resistant bacteria and their drug-resistant genes in both humans and animals.

There are many articles on the analysis of ESBL-producing bacteria and their drug-resistance genes in particular animals. While some review articles have attempted to summarize these studies, most of them have focused on a specific type of bacteria (such as *Escherichia coli* or *Klebsiella pneumoniae*) or only reviewed one type of animal, lacking a comprehensive review. Our objective is to compile all ESBL-producing bacteria isolated from various animals in recent years, providing a comprehensive understanding of the distribution of ESBL-producing bacteria and genes in animals worldwide. This review attempts to underscore the role of animals in the rising incidence of ESBL-producing bacteria and the need for a coordinated effort to address this growing threat.

2. Results

The general findings of the reviewed articles are summarized in Table 1. Samples of ESBL-producing bacteria were mostly obtained from farms in Africa (Egypt, Kenya, Tunisia, Nigeria, and Algeria), Asia (Pakistan, India, Qatar, Iran, Malaysia, China, Saudi Arabia, Bangladesh, and Thailand), Europe (Finland, Portugal, Spain, Netherlands, Germany, France, and Switzerland), North American (USA), and South America (Brazil, Guadeloupe, and Peru). Other sampling locations included the airport, animal clinics, animal shelters, hunting grounds, petting zoos, slaughterhouses, research facilities, universities, and wild colonies. Most samples were obtained from rectal swabs and fresh feces of animals. However, other samples including raw milk, blood and visceral samples, cloacal swabs, uterine swabs, external surface and gut homogenates, urine, pus, and respiratory pathological specimens were also included. The most reported bacteria were *Escherichia coli* and *Klebsiella pneumoniae*. Other Enterobacterales were also in abundance while *Pseudomonas aeruginosa* was only found on the uterine swabs of farm cows, camels, and mares in one study from Saudi Arabia.

Our review included 23 articles on domestic animals, 6 articles on wild animals, and 1 article on both. Other than farm animals, pets, zoo animals, vampire bats, and cockroaches were sampled. Four studies emphasized that the specimens were sourced from diseased animals, including diseased companion animals, diseased horses, diseased cows, camels, mares, and diseased pigs. The compilation of animals screened across different countries is presented in Figure 1a.

Table 2 summarizes the details of the ESBL genes. Most samples were grown using MacConkey agar. Fifteen articles included in our review utilized selective media supplemented with third-generation cephalosporins for initial ESBL screening. Most targeted bacteria were identified by Matrix-Assisted Laser Desorption Ionization–Time-of-Flight (MALDI-TOF) and polymerase chain reaction (PCR). The prevalence of ESBL in the samples varied widely from 0 to 100%. Double-disc synergy test was mostly used for identifying ESBL-producing bacteria. The most detected ESBL genes were *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}. Subtype distribution around the world can be found in Figure 1b. Primers used in the re-

viewed articles are listed in Table 3. No standardized primer was used for each target gene. However, Woodford et al. (2006) was the most highly cited article for primers targeting specific groups of *bla*_{CTX-M}.




Figure 1. (a) Countries that reported the presence of ESBL-producing bacteria in animals. (b) Countries that reported the presence of ESBL-subtype distribution in animals.

Table 1. Studies of ESBL-producing bacteria in animals.

Article	Country	Location	Sample	Animals	Date of Isolation	Bacteria
Venla Johansson et al., 2022 [9]	Finland	airport, animal clinics, animal shelters	rectal swabs or fresh feces	dogs	2017–2018	<i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
Muhammad Shafiq et al., 2022 [10]	Pakistan	farms	rectal swabs or fresh droppings	buffaloes, cattle, sheep, goats, and broilers	no details	<i>Escherichia coli</i>
Rita Tinoco Torres et al., 2022 [11]	Portugal	hunting grounds	rectal swabs	Wild ungulates	October 2018–February 2020	Enterobacterales
Maitane Tello et al., 2022 [12]	Spain	dairy cattle farms	rectal swabs	calves, heifers, and cows	February 2019–October 2020	<i>Escherichia coli</i>
Tilaye Shibbiru Mengistu et al., 2022 [13]	Spain	a highly populated and intensive farming region	cloacal/rectal swabs	turtles, minks, and otters	January 2018–July 2021	Enterobacterales, and some other Gram-negative bacteria
Irene Aldea et al., 2022 [14]	Spain	a commercial laying hen farm	fresh meconium droppings, feces	chicks and hens	March 2016–October 2018	<i>Escherichia coli</i>
Rasha Elkenany et al., 2022 [15]	Egypt	dairy farms	raw cow milk	cows	2018	<i>Shigella</i> species
Teresita d.J. Bello Gonzalez et al., 2022 [16]	Netherlands	dairy farms	rectal swabs	calves	March 2019–May 2020	<i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
Benti D Gelalcha et al., 2022 [17]	USA	dairy farms	bulk tank milk	cows	no details	<i>Escherichia coli</i>
Jannis Göttling et al., 2022 [18]	Germany	petting zoo	rectal swabs	healthy goats	August 2016–June 2017	Enterobacterales
Nagappa Karabasanavar et al., 2022 [19]	India	pig farms	rectal swabs	healthy pigs	April 2019–April 2020	<i>Salmonella</i> species
Md Mazharul Islam et al., 2021 [20]	Qatar	livestock farms, agricultural farms	blood and visceral samples	commensal rodents	August 2019–February 2020	Gram-negative bacilli
Damini P. Khawaskar et al., 2021 [21]	India	dairy farms	rectal swabs	neonatal calves	no details	<i>Escherichia coli</i>
Mehri Haeili et al., 2021 [22]	Iran	a chicken slaughterhouse	cloacal swabs	slaughtered broilers	no details	<i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
Erkihun Aklilu et al., 2022 [23]	Malaysia	farms	cloacal swabs	broiler chickens	no details	<i>Escherichia coli</i>

Table 1. Cont.

Article	Country	Location	Sample	Animals	Date of Isolation	Bacteria
Máisa Fabiana Menck-Costa et al., 2022 [24]	Brazil	broiler farms	cloacal swabs	broiler chickens	March 2019–July 2020	<i>Escherichia coli</i>
James G Ndukui et al., 2021 [25]	Kenya	poultry production centers	cloacal swabs	chickens	November 2020–February 2021	Enterobacterales
Xiaoyan Su et al., 2022 [26]	China	Chengdu Research Base of Giant Panda Breeding	fresh feces	captive giant pandas	2018–2019	<i>Klebsiella pneumoniae</i>
Gaëlle Gruel et al., 2022 [27]	Guadeloupe (French West Indies)	animal shelters and veterinary clinics	rectal swabs	dogs and cats	June 2019–September 2019	Enterobacterales
Samy F. Mahmoud et al., 2022 [28]	Saudi Arabia	farms	uterine swabs	diseased cow, camel, and mare	May 2020–February 2021	<i>Pseudomonas aeruginosa</i>
Md Saiful Islam et al., 2021 [29]	Bangladesh	no details	fresh feces	migratory birds	November 2019–November 2020	<i>Escherichia coli</i>
Sarra Landolsi et al., 2022 [30]	Tunisia	a collective catering, houses, and a hospital	external surface and gut homogenates	cockroaches	July 2017–June 2018	Enterobacterales
Raquel Garcia-Fierro et al., 2022 [31]	France	no details	Urine, pus, and respiratory pathological specimens	diseased dogs, cats, horses, cattle, and birds	2010–2018	<i>Klebsiella pneumoniae</i>
Adriana Belas et al., 2022 [32]	Portugal	faculty of veterinary medicine	urine	dogs and cats	1999–2015	<i>Escherichia coli</i>
Mabel Kamweli Aworh et al., 2022 [33]	Nigeria	abattoirs	Cecal contents from the cecum	slaughtered beef cattle	May 2020–December 2020	<i>Escherichia coli</i>
Magdalena Nüesch-Inderbinen et al., 2022 [34]	Switzerland	organic and conventional dairy farms	fresh feces	calves	September 2020	Enterobacterales
Ahmed Samir et al., 2022 [35]	Egypt	equine farms	rectal swabs and nasal swabs	diseased adult horses	August 2020–March 2021	<i>Klebsiella pneumoniae</i>
Lotfi Loucif et al., 2021 [36]	Algeria	nests and a colony	fresh feces	white stork	May 2019	Enterobacterales

Table 1. Cont.

Article	Country	Location	Sample	Animals	Date of Isolation	Bacteria
Julio A Benavides et al., 2021 [37]	Peru	colonies	rectal swabs	vampire bats	2015 (October), 2017 (March to May), and 2018 (February and March)	<i>Escherichia coli</i>
		farms located nearby vampire bat colonies	fresh feces	cows, pigs, goats, sheep, and donkeys	2015	<i>Escherichia coli</i>
Suthathip Trongjit et al., 2022 [38]	Thailand	farms	rectal swabs	pigs	2007–2018	<i>Escherichia coli</i>

Table 2. Characteristics of ESBL genes in animals in the review.

Article	Selective Media	Target Identification	Total Number	ESBL Number	%	ESBL Test	ESBL Genes Test	ESBL Genes and Number
Venla Johansson et al., 2022 [9]	MacConkey agar with cefotaxime (1 mg/L)	MALDI-TOF	60	47	78.3%	double-disc synergy test	WGS	<i>bla</i> _{TEM} (25), <i>bla</i> _{SHV} (2), <i>bla</i> _{CTX-M-1} (7), <i>bla</i> _{CTX-M-3} (1), <i>bla</i> _{CTX-M-15} (36), <i>bla</i> _{CTX-M-55} (2), <i>bla</i> _{CTX-M-8} (1), <i>bla</i> _{CTX-M-65} (1)
Muhammad Shafiq et al., 2022 [10]	MacConkey agar	PCR (<i>uidA</i> gene)	153	75	49.0%	double-disc synergy test	PCR	<i>bla</i> _{TEM} (37), <i>bla</i> _{SHV} (32), <i>bla</i> _{CTX-M-1} group (35), <i>bla</i> _{CTX-M-2} group (5), <i>bla</i> _{CTX-M-8} group (1), <i>bla</i> _{CTX-M-9} group (32), <i>bla</i> _{CTX-M-25} group (3)
Rita Tinoco Torres et al., 2022 [11]	MacConkey agar with antibiotic ¹	biochemical reaction (API20E galleries)	151	4	2.6%	Characteristic phenotypic synergism with ESBL genes	PCR	<i>bla</i> _{TEM} (60), <i>bla</i> _{SHV} (3), <i>bla</i> _{CTX-M} (4) [<i>CTX-M-14</i> (2), <i>CTX-M-15</i> (1), <i>CTX-M-98</i> (1)]

Table 2. Cont.

Article	Selective Media	Target Identification	Total Number	ESBL Number	%	ESBL Test	ESBL Genes Test	ESBL Genes and Number
Maitane Tello et al., 2022 [12]	MacConkey agar with cefotaxime (1 mg/L)	PCR (uidA gene)	41	39	95.1%	ESBL genes	WGS	<i>bla</i> _{TEM} (17), <i>bla</i> _{SHV} (1), <i>bla</i> _{CTX-M-1} (9), <i>bla</i> _{CTX-M-14} (12), <i>bla</i> _{CTX-M-15} (9), <i>bla</i> _{CTX-M-27} (3), <i>bla</i> _{CTX-M-32} (5)
Tilaye Shibbiru Mengistu et al., 2022 [13]	MacConkey agar with ceftriaxone (1 mg/L)	API® biochemical test strips or automated system (VITEK 2)	131	4	3.1%	ESBL genes	PCR	<i>bla</i> _{TEM} (0), <i>bla</i> _{CTX-M} (4) [_{CTX-M-15} (4)]
Irene Aldea et al., 2022 [14]	MacConkey agar with cefotaxime (1 mg/L)	PCR, API 20-E kit, or whole genome sequencing	47	29	61.7%	ESBL genes ⁸	WGS	<i>bla</i> _{TEM} (19), <i>bla</i> _{SHV} (9), <i>bla</i> _{CTX-M-1} (19), <i>bla</i> _{CTX-M-14} (1)
Rasha Elkenany et al., 2022 [15]	Salmonella-Shigella agar, MacConkey agar, and xylose-lysine-deoxycholate agar	Biochemical reaction ⁴	16	4	25.0%	double-disc synergy test	PCR	<i>bla</i> _{TEM} (16), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M} (4)
Teresita d.J. Bello Gonzalez et al., 2022 [16]	MacConkey agar with cefotaxime (1 mg/L)	MALDI-TOF	254	254	100.0%	ESBL genes	PCR	<i>bla</i> _{TEM} (254), <i>bla</i> _{SHV} (174), <i>bla</i> _{CTX-M-14} (174), <i>bla</i> _{CTX-M-15} (80)
Benti D Gelalcha et al., 2022 [17]	CHROMagar™ <i>E. coli</i> agar	PCR (uidA gene)	14	4	28.6%	ESBL genes	PCR	<i>bla</i> _{TEM} (0), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M} (4)
Jannis Göttling et al., 2022 [18]	Oxoid Brilliance ESBL agar	automated system (VITEK 2)	300	1	0.3%	Commercial disc test system (D68C ESBL/AmpC ID, MAST group Diagnostics)	PCR	<i>bla</i> _{TEM} (0), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M-1} (1), <i>bla</i> _{CTX-M-2} (0), <i>bla</i> _{CTX-M-9} (0)
Nagappa Karabasanavar et al., 2022 [19]	Xylose-lysine-deoxycholate agar, Brilliant green agar, Bismuth sulfite agar, Hektoen Enteric agar	Biochemical reaction ⁵	22	12	54.5%	ESBL genes	PCR	<i>bla</i> _{TEM} (12), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M-1} (0), <i>bla</i> _{CTX-M-2} (0), <i>bla</i> _{CTX-M-9} (0)
Md Mazharul Islam et al., 2021 [20]	MacConkey agar, Hektoen enteric agar, Eosin methylene blue agar	automated system (VITEK 2)	68	9	13.2%	VITEK 2 AST-GN cards	no test	no test

Table 2. Cont.

Article	Selective Media	Target Identification	Total Number	ESBL Number	%	ESBL Test	ESBL Genes Test	ESBL Genes and Number
Damini P. Khawaskar et al., 2021 [21]	MacConkey agar and Eosin methylene blue agar	biochemical reaction (IMViC Test)	280	120	42.9%	combination disk method	PCR	<i>bla</i> _{TEM} (10), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M-1} group (34), <i>bla</i> _{CTX-M-2} group (0), <i>bla</i> _{CTX-M-8} group (2), <i>bla</i> _{CTX-M-9} group (1), <i>bla</i> _{CTX-M-25} group (0)
Mehri Haeili et al., 2021 [22]	no details	no details	21	0	0.0%	combination disk method	no test	no test
Erkihun Aklilu et al., 2022 [23]	MacConkey and Eosine Methylene Blue agars	PCR (<i>E. coli</i> specific gene)	49	12	24.5%	ESBL genes	PCR	<i>bla</i> _{TEM} (12), <i>bla</i> _{CTX-M} (0)
Máisa Fabiana Menck-Costa et al., 2022 [24]	MacConkey agar with/without antibiotics ²	biochemical reaction ⁶	360	198	55.0%	double-disc synergy test	PCR	<i>bla</i> _{CTX-M-1} group (153), <i>bla</i> _{CTX-M-2} group (61), <i>bla</i> _{CTX-M-8} group (5), <i>bla</i> _{CTX-M-9} group (0), <i>bla</i> _{CTX-M-25} group (0)
James G Ndukupi et al., 2021 [25]	no details	biochemical reaction	544	30	5.5%	phenotypic resistance profiles and then ESBL genes	PCR	<i>bla</i> _{TEM} (14), <i>bla</i> _{SHV} (5), <i>bla</i> _{CTX-M} (11)
Xiaoyan Su et al., 2022 [26]	no details	16 s rDNA and biochemical reaction	211	3	1.4%	double-disc synergy test	PCR	<i>bla</i> _{TEM} (2), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M} (3), <i>bla</i> _{GES} (0), <i>bla</i> _{PER} (0), <i>bla</i> _{VEB} (0)
Gaëlle Gruel et al., 2022 [27]	CHROMagar™ CCA with ceftriaxone (4 mg/L)	API 20-E kit	185	14	7.6%	double-disk synergy test	WGS	<i>bla</i> _{TEM} (1), <i>bla</i> _{SHV} (1), <i>bla</i> _{CTX-M-1} (11), <i>bla</i> _{CTX-M-15} (3)
Samy F. Mahmoud et al., 2022 [28]	Pseudomonas cetrimide agar	automated system (VITEK 2)	44	20	45.5%	double-disk synergy test	PCR	<i>bla</i> _{TEM} (18), <i>bla</i> _{SHV} (8), <i>bla</i> _{CTX-M} (11)
Md Saiful Islam et al., 2021 [29]	Eosin methylene blue agar	biochemical reaction ⁷	55	21	38.2%	double-disk synergy test	PCR	<i>bla</i> _{TEM} (20), <i>bla</i> _{SHV} (9), <i>bla</i> _{CTX-M} (18)
Sarrah Landolsi et al., 2022 [30]	MacConkey agar with cefotaxime (1 mg/L)	MALDI-TOF	144	22	15.3%	double-disk synergy test	PCR	<i>bla</i> _{TEM} (9), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M} (15) [<i>bla</i> _{CTX-M-1} (7), <i>bla</i> _{CTX-M-15} (8)]
Raquel Garcia-Fierro et al., 2022 [31]	no details, but cefoxitin- and/or ceftiofur-resistant	MALDI-TOF	105	52	49.5%	ESBL genes	WGS	<i>bla</i> _{SHV} (2), <i>bla</i> _{CTX-M-1} (3), <i>bla</i> _{CTX-M-3} (1), <i>bla</i> _{CTX-M-14} (4), <i>bla</i> _{CTX-M-15} (42)

Table 2. Cont.

Article	Selective Media	Target Identification	Total Number	ESBL Number	%	ESBL Test	ESBL Genes Test	ESBL Genes and Number
Adriana Belas et al., 2022 [32]	no details, but Third-generation cephalosporin-resistant	PCR (gadA gene)	35	14	40.0%	ESBL genes	PCR	<i>bla</i> _{CTX-M-1} (2), <i>bla</i> _{CTX-M-1-like} (2), <i>bla</i> _{CTX-M-9} (1), <i>bla</i> _{CTX-M-15} (7), <i>bla</i> _{CTX-M-32} (3)
Mabel Kamweli Aworh et al., 2022 [33]	MacConkey agar with cefotaxime (1 mg/L)	biochemical reaction (commercially Microbact GNB 24E kit)	272	44	16.2%	combination disk method	WGS	<i>bla</i> _{CTX-M-14} (1), <i>bla</i> _{CTX-M-15} (41), <i>bla</i> _{CTX-M-55} (1)
Magdalena Nüesch-Inderbilen et al., 2022 [34]	Rapid ¹ <i>E. coli</i> two agar plates	MALDI-TOF	196	21	10.7%	Brilliance ESBL agar plates	PCR	<i>bla</i> _{TEM} (0), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M-1} (7), <i>bla</i> _{CTX-M-3} (4), <i>bla</i> _{CTX-M-14} (2), <i>bla</i> _{CTX-M-15} (8)
Ahmed Samir et al., 2022 [35]	MacConkey agar with cefotaxime (2 mg/L)	PCR (Klebsiella <i>gyrA</i> gene, ITS gene)	100	13	13.0%	double-disc synergy test	PCR	<i>bla</i> _{TEM} (13), <i>bla</i> _{SHV} (13), <i>bla</i> _{CTX-M} (12)
Lotfi Loucif et al., 2021 [36]	MacConkey agar with antibiotics ³	MALDI-TOF	42	8	19.0%	double-disc synergy test	PCR	<i>bla</i> _{TEM} (20), <i>bla</i> _{SHV} (4), <i>bla</i> _{CTX-M} (19)
Julio A Benavides et al., 2021 [37]	ChromID ESBL agar	MALDI-TOF	388	20	5.2%	ChromID ESBL agar	WGS	<i>bla</i> _{TEM} (17), <i>bla</i> _{CTX-M-3} (2), <i>bla</i> _{CTX-M-14} (0), <i>bla</i> _{CTX-M-15} (7), <i>bla</i> _{CTX-M-55} (8), <i>bla</i> _{CTX-M-65} (1)
			134	65	48.5%	ChromID ESBL agar	WGS	<i>bla</i> _{TEM} (14), <i>bla</i> _{CTX-M-3} (1), <i>bla</i> _{CTX-M-14} (3), <i>bla</i> _{CTX-M-15} (2), <i>bla</i> _{CTX-M-55} (7), <i>bla</i> _{CTX-M-65} (3)
Suthathip Trongjit et al., 2022 [38]	no details	no details	454	112	24.7%	combination disk method	PCR	<i>bla</i> _{TEM} (81), <i>bla</i> _{SHV} (0), <i>bla</i> _{CTX-M-14} (61), <i>bla</i> _{CTX-M-55} (48)

MALDI-TOF: Matrix-Assisted Laser Desorption Ionization–Time-of-Flight, PCR: polymerase chain reaction, WGS: whole genome sequencing. ¹ Including ampicillin (100 µg/mL), cefotaxime (1 µg/mL), meropenem (0.5 µg/mL), ciprofloxacin (1 µg/mL), or tetracycline (100 µg/mL). ² Ciprofloxacin, cefotaxime, and ciprofloxacin + cefotaxime, at a final concentration of 8 mg/mL. ³ 2 µg/mL cefotaxime, 2 µg/mL ertapenem, 9 µg/mL imipenem, and 3 µg/mL colistin, respectively. ⁴ Triple sugar iron agar, lysine iron agar, methyl red, Voges–Proskauer broth, the indole test, urea agar, Simmon’s citrate agar, and a motility test. ⁵ Methyl red, Voges–Proskauer, indole, Simmon’s citrate, urease, triple sugar iron agar, lysine decarboxylase, phenol red dulcitol, KCN, and malonate. ⁶ Triple sugar iron agar, indole production, Simmon’s citrate, urease production, lysine decarboxylation, and sorbitol and cellobiose fermentation tests. ⁷ Catalase test, coagulase test, sugar fermentation tests, methyl red test, Voges–Proskauer test, and indole test. ⁸ This article does not classify *bla*_{TEM} as an ESBL gene.

Table 3. Primers used for detecting ESBL-encoding genes in the review.

Target	Forward Primer (5'-3')	Reverse Primer (5'-3')	Articles	Reference
<i>bla_{TEM}</i>	CATTCCGTGTCGCCCTTATTC	CGTTCATCCATAGTTGCCTGAC	[11,19,26]	Dallenne et al., 2010 [39]
	CATTCCGTGTCGCCCTTATTC	TCCATAGTTGCCTGACTCCC	[29]	Randall et al., 2004 [40]
	CATTCCGTGTCGCCCTTATTC	CCAATGCTTAATCAGTGAGGC	[17]	Strauss et al., 2015 [41]
	ATGAGTATTCAACATTCCG	CCAATGCTTAATCAGTGAGGC	[25]	Gootz et al., 2009 [42]
	ATGAGTATTCAACATTCCG	CTGACAGTTACCAATGCTTA	[21,30]	Bhattacharjee et al., 2007 [43], Christophy et al., 2017 [44]
	ATGAGTATTCAACATTCCG	TTAATCAGTGAGGCACCTAT	[18]	Grobner et al., 2009 [45]
	TCTGCTATGTGGTGCGGTA	GTCCTCCGATCGTTGTCAGA	[36]	Ly et al., 2019 [46]
	GCATCTTACGGATGGCATGA	GTCCTCCGATCGTTGTCAGA	[28]	Hosu et al., 2021 [47]
	TCGGGGAAATGTGCGCG	TGCTTAATCAGTGAGGCACC	[34]	Pitout et al., 1998 [48]
	CGCCGCATACACTATTCTCAGAATGA	ACGCTCACCGCTCCAGATTAT	[35]	Fang et al., 2008 [49]
	GCGGAACCCCTATTG	TCTAAAGTATATATGAGTAAACTTGGTCTGAC	[13,38]	Darwich et al., 2019 [2], Hasman et al., 2005 [50]
	ATAAAATCTTGAAGACGAAA	GACAGTTACCAATGCTTAATC	[10,23]	Ali et al., 2017 [51], Weill et al., 2004 [52]
	<i>bla_{SHV}</i>	ATCAGCAATAAACCAGC	CCCCGAAGAACGTTTTTC	[15]
CACTCAAGGATGTATTGTG		TTAGCGTTGCCAGTGCTCG	[34]	Pitout et al., 1998 [48]
TTCGCCTGTGTATTATCTCCCTG		TTAGCGTTGCCAGTYTCG	[38]	Hasman et al., 2005 [50]
GGGTTATTCTTATTTGTCGC		TTAGCGTTGCCAGTGCTC	[10]	Ali et al., 2017 [51]
CTTATCGGCCCTCACTCAA		AGGTGCTCATATGGGAAAG	[35]	Fang et al., 2008 [49]
TCCCATGATGAGCACCTTAAA		TCCTGCTGGCGATAGTGGAT	[28,36]	Hosu et al., 2021 [47], Ly et al., 2019 [46]
AGCCGCTTGAGCAAATTAAC		ATCCCGCAGATAAATCACCAC	[11,19,26]	Dallenne et al., 2010 [39]
AGGATTGACTGCCTTTTTG		ATTTGCTGATTCGCTCG	[15]	Colom et al., 2003 [53]
GCCGGTTATTCTTATTGTGCG		ATGCCGCCGCCAGTCA	[17]	Rayamajhi et al., 2008 [54]
GCAAAACGCCGGTTATTC		GGTTAGCGTTGCCAGTGCT	[18]	Grobner et al., 2009 [45]
CCTTAAAGTAGTGCTCTGC		TTCGCTGACCGGCGAGTAGT	[21]	Lob et al., 2015 [55]
GGTTATGCGTTATATTCGCC		TTAGCGTTGCCAGTGCTC	[30]	Christophy et al., 2017 [44]
ATGCGTTATWTTGCGCTGTGT		TTAGCGTTGCCAGTGCTCG	[25]	El-Shazly et al., 2015 [56]
TCGCCTGTGTATTATCTCCC	CGCAGATAAATCACCACAATG	[29]	Van et al., 2008 [57]	

Table 3. Cont.

Target	Forward Primer (5'-3')	Reverse Primer (5'-3')	Articles	Reference
<i>bla</i> _{CTX-M}	ATGTGCAGYACCAGTAARGTKATGGC	TGGGTRAARTARGTSACCAGAAAYCAGCGG	[13,15,25,26,29,35,38]	Darwich et al., 2019 [2], Archambault et al., 2006 [58], Ahmed et al., 2013 [59], Su et al., 2022 [26], Gundran et al., 2019 [60], Fang et al., 2008 [49], Hasman et al., 2005 [50]
	ATGTGCAGYACCAGTAARGT	TGGGTRAARTARGTSACCAGA	[30]	Christophy et al., 2017 [44]
	CGATGTGCAGTACCAGTAA	TTAGTGACCAGAATCAGCGG	[38]	Batchelor et al., 2005 [61]
	TTTGCGATGTGCAGTACCAGTAA	CGATATCGTTGGTGGTGCCATA	[17,32]	Edelstein et al., 2003 [62]
	CGCTTTGCGATGTGCAG	ACCGCGATATCGTTGGT	[10,18]	Ali et al., 2017 [51], Grobner et al., 2009 [45]
	CCCATGGTTAAAAAACAACACTGC	CAGCGCTTTTGCCGTCTAAG	[23]	Horton et al., 2011 [63]
	ATGAGYACCAGTAARGTKATGGC	ATCACKCGGRTCGCCIGGRAT	[28]	Hosu et al., 2021 [47]
<i>bla</i> _{CTX-M} group 1	AAAAATCACTGCGCCAGTTC	AGCTTATTCATCGCCACGTT	[11,21,24,32,34]	Woodford et al., 2006 [64]
	TTAGGAARTGTGCCGCTGYA	CGATATCGTTGGTGGTRCCAT	[19,38]	Dallenne et al., 2010 [39]
	GTTGCTCTCTCCAGAATAAGG	CAGCACTTTTGCCGTCTAAG	[18]	Pfeifer et al., 2009 [65]
<i>bla</i> _{CTX-M} group 2	CGACGCTACCCCTGCTATT	CCAGCGTCAGATTTTTCAGG	[11,21,24,32,34]	Woodford et al., 2006 [64]
	CGTTAACGGCACGATGAC	CGATATCGTTGGTGGTRCCAT	[19,38]	Dallenne et al., 2010 [39]
<i>bla</i> _{CTX-M} group 9	CAAAGAGAGTGCAACGGATG	ATTGGAAAGCGTTCATCACC	[11,21,24,32,34]	Woodford et al., 2006 [64]
	TCAAGCCTGCCGATCTGGT	TGATTCTCGCCGCTGAAG	[19,38]	Dallenne et al., 2010 [39]
	ACACGGATTGACCGTATTGG	TGATTCTCGCCGCTGAAG	[18]	Wetzker et al., 2019 [66]
	GCAGTACAGCGACAATACCG	TATCATTGGTGGTGCCGTAG	[18]	Grobner et al., 2009 [45]
<i>bla</i> _{CTX-M} group 8	TCGCGTTAAGCGGATGATGC	AACCCACGATGTGGGTAGC	[11,21,24,32,34]	Woodford et al., 2006 [64]
	AACRCRCAGACGCTCTAC	TCGAGCCGGAASGTGYAT	[38]	Dallenne et al., 2010 [39]
<i>bla</i> _{CTX-M} group 25	GCACGATGACATTCGGG	AACCCACGATGTGGGTAGC	[11,21,24,32,34]	Woodford et al., 2006 [64]
	AACRCRCAGACGCTCTAC	TCGAGCCGGAASGTGYAT	[38]	Dallenne et al., 2010 [39]
<i>bla</i> _{GES}	AGTCGGCTAGACCGAAAG	TTTGCCGTGCTCAGGAT	[26]	Su et al., 2022 [26]
<i>bla</i> _{PER}	GCTCCGATAATGAAAGCG	TTCGGCTTGACTCGGCTGA	[26]	Su et al., 2022 [26]
<i>bla</i> _{VEB}	CATTTCCCGATGCAAAGCGT	CGAAGTTTCTTTGGACTCTG	[26]	Su et al., 2022 [26]

3. Discussion

The results of the literature review provide a comprehensive comparison with previous studies on ESBL-producing bacteria in animals. While most previous studies have focused on limited geographic regions and animal populations, the current literature review offers a broader perspective on the highly diverse nature of ESBL-producing bacteria. This review provides insights into the distribution and occurrence of ESBL-producing bacteria in different regions and animal populations, helping to fill gaps in our understanding of this important issue.

Although previous studies have established the spread of ESBL-producing Enterobacteriales in food-producing animals and companion pets around the world [67,68], this review highlights the presence of ESBL-producing bacteria in wild vampire bats, wild ungulates, and cockroaches. These findings suggest that the spread of ESBL-producing bacteria is not limited to domesticated animals, but can also occur in wild animal populations. The presence of ESBL-producing bacteria in wild animals can have significant implications for their health, as well as for the health of other animal populations and humans that may encounter them. It is important to consider the potential sources of ESBL-producing bacteria in wild animals, including exposure to contaminated food and water sources, contact with domesticated animals and their environment, or exposure to antibiotics in the environment [69,70]. The spread of ESBL-producing bacteria in wild animal populations can also have ecological consequences, such as altering the balance of microbial communities and affecting the health of the animals and their habitat. It is crucial to continue monitoring the presence of ESBL-producing bacteria in wild animal populations and to implement strategies to reduce their spread. The One Health approach, which recognizes the interconnections between human, animal, and environmental health, is crucial in addressing the issue of ESBL-producing bacteria in wild animals. In the past, WHO had launched an integrated global surveillance on ESBL-producing *E. coli* with the same approach [71]. Similar programs covering a wider range of ESBL-producing bacteria may be considered.

Samples in this review were mostly obtained from Enterobacteriales-rich areas such as the rectum and fresh feces. However, ESBL-producing bacteria were also found in raw milk and blood and visceral samples of animals in this review [15,17,20]. Unlike most other samples where ESBL-producing genes were found in Enterobacteriales, one study reviewed showed the presence of *Pseudomonas aeruginosa* in uterine swabs of farm animals [28]. The potential for animals to act as reservoirs and vectors of resistance genes is therefore not limited to Enterobacteriales found in food-producing animals and pets in contact with humans and antibiotics. One study in Kenya was conducted to collect cloacal swabs from the chickens and fecal samples from the farms. Out of the 544 cloacal isolates of Enterobacteriales, 30 were found to contain ESBL genes. Among these, 14 isolates had *bla*_{TEM}, 5 had *bla*_{SHV}, and 11 had *bla*_{CTX-M}. In contrast, among the 47 human isolates, 3 were found to contain ESBL genes, including 2 with *bla*_{TEM} and 1 with *bla*_{CTX-M} [25].

There are many kinds of ESBL-encoding genes, including *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTX-M}, *bla*_{GES}, *bla*_{VEB}, *bla*_{IRT}, *bla*_{CMT}, *bla*_{BEL}, *bla*_{TLA}, and *bla*_{PER} [5]. However, most studies reviewed that investigated bacteria from animals only screened for *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}. Genes including *bla*_{GES}, *bla*_{VEB}, *bla*_{IRT}, *bla*_{CMT}, *bla*_{BEL}, *bla*_{TLA}, and *bla*_{PER} were rarely described and did not occur as frequently as the former three. This is possibly due to the genes being encoded on the chromosomes and not plasmids [8,72]. Furthermore, researchers used various primers for the detection and sequencing of the target genes. The results of this review draw attention to the need for standardized and comprehensive surveillance of ESBL-producing bacteria in animal populations. The limited screening for only a few types of ESBL-encoding genes, such as *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}, may not fully capture the diversity and distribution of ESBL-producing bacteria in animal populations. Standardized surveillance covering a wider range of animals and regions will be necessary to better understand the spread of ESBL-producing bacteria and the potential impact on human and animal health. In addition, the use of different primers for the detection and sequencing of ESBL-encoding genes can lead to variability in the results and limit the comparability of studies [73]. Standardized protocols for the detection and sequencing of ESBL-encoding genes are necessary to ensure consistent

and accurate results, which is the cornerstone of a better understanding of the spread of these bacteria and their potential impact on human and animal health.

In recent years, there has been a growing concern over the emergence of *bla*_{ESBL}-harboring plasmids in animal isolates. These plasmids are capable of transmitting *bla*_{ESBL} genes among different bacterial species and even among different hosts, including animals and humans [74,75]. Studies have shown that *bla*_{ESBL}-harboring plasmids can be found in various animal isolates, including those from bovine, camels, dogs, cats, goats, and poultry [10,14,76–78]. These plasmids can spread rapidly across and within bacterial populations, leading to the dissemination of antibiotic-resistance genes and the emergence of multidrug-resistant bacteria [79]. Overall, the occurrence of *bla*_{ESBL}-harboring plasmids in animal isolates highlights the need for effective surveillance and control measures to limit the spread of antibiotic resistance in both animal and human populations.

PCR with oligonucleotide primers that are specific for a β -lactamase gene was the most common and simplest molecular method used to identify the presence of a β -lactamase enzyme belonging to a specific family. The chosen primers were designed to anneal to regions where no point mutations were known to occur [8,72]. However, in some cases, specific primers may have had special restrictions. For example, the *bla*_{CTX-M} primer Forward (5'-CGCTTTGCGATGTGCAG-3') and Reverse (5'-ACCGCGATATCGTTGGT-3') should not be used to detect CTX-M enzymes in *Klebsiella oxytoca* as it would result in amplifying chromosomal *bla*_{oxy} genes [80]. However, the direct comparison of the sensitivity and specificity of different primers in detecting specific ESBL genes is lacking. Therefore, exploring the impact of different primers on *bla*_{ESBL} epidemiology may be a potential research direction.

Though the presence of ESBL-producing bacteria could be seen around the world from this review, regions such as Australia, Canada, and Russia were not covered. This may be due to the fewer numbers of literature reviewed. The prevalence of the ESBL-producing bacteria ranged from 0–100% in this review. Results varied widely among different species and regions. Further research in different regions and animal populations is needed to gain a more comprehensive understanding of the distribution of ESBL-producing bacteria in animals. To limit the spread of ESBL-producing bacteria in animals, the development of new strategies, including the use of alternative treatments, improved animal husbandry practices, and increased public awareness are also vital.

Our review is subject to significant limitations. Specifically, our use of only one database (PubMed) and a limited set of keywords, as well as our exclusion of non-English literature. These may have resulted in some relevant publications being overlooked.

4. Materials and Methods

4.1. Literature Search Strategy

Using a thorough PubMed literature search from 1 January 2020 to 30 June 2022, studies that investigated bacteria from animals (whether wild or domestic) with details of ESBLs were included along with current contents and references from relevant articles. We combined the medical MeSH terminology with free-text terms to conduct a systematic literature search. These were the four keyword combinations we used to search: [(Animals) AND (extended-spectrum beta-lactamase)], [(Animals) AND ESBL], ["Animals" [Mesh] AND (extended-spectrum beta-lactamase)], and ["Animals" [Mesh] AND ESBL]. The bibliographic search was carried out by two researchers. The review protocol is provided as Supplementary Materials File S1.

4.2. Inclusion and Exclusion Criteria

The inclusion criteria include: (1) cultivation of bacteria from animal specimens, whether the animal is healthy or sick; (2) conducting ESBL testing on the bacteria, whether it is phenotype or genotype; and (3) the language of publication was English. The exclusion criteria were as follows: (1) specimens from humans or the surrounding environment of animals were excluded; (2) specimens from animals, humans, and the environment, with no clear distinction between them, were also excluded; and (3) specimens that may be

contaminated by environmental or human factors were excluded, such as dairy products, supermarket-packaged raw meat, poultry litter, and pooled feces. However, raw milk and fresh feces are acceptable specimens, as we believe the probability of bacteria cultured from these two types of specimens being contaminated by environmental or human factors is low.

4.3. Study Selection

Our search uncovered 2430 bibliographic references to articles published between 1 January 2021 and 30 June 2022. Thereafter, 1187 duplicate records were removed. Finally, 1243 references remained for screening. The PRISMA 2020 flow diagram [81] for literature screening can be viewed in Figure 2. After the screening of the 1243 records, 1123 records did not match the type of articles we wanted to include. Hence, 120 pieces of full-text literature were assessed for eligibility. Sixty-five of them were excluded because the samples were from the surrounding environment of animals, not from animals themselves. Forty-three of them were excluded because the samples were not only from animals but also from humans or the environment, which could not be distinguished based on the content of the article. Twelve articles were excluded because no denominator (whether the number of animals, number of samples, or number of cultured bacteria) was provided. Finally, 30 documents were selected for further review and analysis.




Figure 2. Flow diagram of the study selection process.

4.4. Data Extraction

We extracted data from all selected literature using a standardized table. The data were grouped as follows: author, date of publication, countries, sampling date and location, sample type, animal species, targeted bacteria, selective media, methods for target identification, the number of denominators, the number of ESBL target, methods for detecting ESBL, methods for detecting ESBL genes, and the number of particular ESBL genes. The collected data were entered into standardized data extraction sheets using Microsoft Excel 2019 (Microsoft Corp, Seattle, WA, USA) for data extraction.

5. Conclusion

The results of this systematic literature review show that ESBL-producing bacteria are present in animals from various countries around the world. We focused on articles where samples were obtained from animals, excluding data from the environment or humans. The most common sources of these bacteria were farm animals, and the most frequently isolated bacteria were *E. coli* and *K. pneumoniae*. The prevalence of ESBL in the samples varied widely and the most commonly detected ESBL genes were *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}.

The presence of ESBL-producing bacteria in animals highlights the importance of the One Health approach to address the issue of antibiotic resistance. Further research is needed to better understand the epidemiology and mechanisms of the spread of ESBL-producing bacteria in animal populations and their potential impact on human and animal health.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/antibiotics12040661/s1>, File S1: Review Protocol. Reference [82] is cited in the supplementary materials.

Author Contributions: Conceptualization: C.-H.T. and P.-Y.L.; Methodology: C.-H.T.; Formal analysis: C.-H.T., C.-W.L. and P.-Y.L.; Investigation: C.-H.T. and P.-Y.L.; Data Curation: C.-H.T., C.-W.L. and P.-Y.L.; Writing—Original Draft: C.-H.T. and C.-W.L.; Writing—Review and Editing: P.-Y.L.; Funding acquisition: P.-Y.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Science and Technology Council, grant number 110-2314-B-075A-011, and Taichung Veterans General Hospital, grant numbers TCVGH-1113901D and TCVGH-1113901C.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *Lancet* **2022**, *399*, 629–655. [[CrossRef](#)] [[PubMed](#)]
2. Darwich, L.; Vidal, A.; Seminati, C.; Albamonte, A.; Casado, A.; Lopez, F.; Molina-Lopez, R.A.; Migura-Garcia, L. High prevalence and diversity of extended-spectrum beta-lactamase and emergence of OXA-48 producing Enterobacterales in wildlife in Catalonia. *PLoS ONE* **2019**, *14*, e0210686. [[CrossRef](#)] [[PubMed](#)]
3. Dandachi, I.; Sokhn, E.S.; Dahdouh, E.A.; Azar, E.; El-Bazzal, B.; Rolain, J.M.; Daoud, Z. Prevalence and Characterization of Multi-Drug-Resistant Gram-Negative Bacilli Isolated from Lebanese Poultry: A Nationwide Study. *Front. Microbiol.* **2018**, *9*, 550. [[CrossRef](#)]
4. Tang, K.L.; Caffrey, N.P.; Nobrega, D.B.; Cork, S.C.; Ronksley, P.E.; Barkema, H.W.; Polachek, A.J.; Ganshorn, H.; Sharma, N.; Kellner, J.D.; et al. Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: A systematic review and meta-analysis. *Lancet Planet Health* **2017**, *1*, e316–e327. [[CrossRef](#)] [[PubMed](#)]
5. Castanheira, M.; Simner, P.J.; Bradford, P.A. Extended-spectrum beta-lactamases: An update on their characteristics, epidemiology and detection. *JAC Antimicrob. Resist.* **2021**, *3*, dlab092. [[CrossRef](#)]

6. Zhu, F.H.; Rodado, M.P.; Asmar, B.I.; Salimnia, H.; Thomas, R.; Abdel-Haq, N. Risk factors for community acquired urinary tract infections caused by extended spectrum beta-lactamase (ESBL) producing *Escherichia coli* in children: A case control study. *Infect. Dis.* **2019**, *51*, 802–809. [[CrossRef](#)]
7. Tacconelli, E.; Gorska, A.; De Angelis, G.; Lammens, C.; Restuccia, G.; Schrenzel, J.; Huson, D.H.; Carevic, B.; Preotescu, L.; Carmeli, Y.; et al. Estimating the association between antibiotic exposure and colonization with extended-spectrum beta-lactamase-producing Gram-negative bacteria using machine learning methods: A multicentre, prospective cohort study. *Clin. Microbiol. Infect.* **2020**, *26*, 87–94. [[CrossRef](#)]
8. Paterson, D.L.; Bonomo, R.A. Extended-spectrum beta-lactamases: A clinical update. *Clin. Microbiol. Rev.* **2005**, *18*, 657–686. [[CrossRef](#)]
9. Johansson, V.; Nykasenoja, S.; Myllyniemi, A.L.; Rossow, H.; Heikinheimo, A. Genomic characterization of ESBL/AmpC-producing and high-risk clonal lineages of *Escherichia coli* and *Klebsiella pneumoniae* in imported dogs with shelter and stray background. *J. Glob. Antimicrob. Resist.* **2022**, *30*, 183–190. [[CrossRef](#)]
10. Shafiq, M.; Rahman, S.U.; Bilal, H.; Ullah, A.; Noman, S.M.; Zeng, M.; Yuan, Y.; Xie, Q.; Li, X.; Jiao, X. Incidence and molecular characterization of ESBL-producing and colistin-resistant *Escherichia coli* isolates recovered from healthy food-producing animals in Pakistan. *J. Appl. Microbiol.* **2022**, *133*, 1169–1182. [[CrossRef](#)]
11. Torres, R.T.; Cunha, M.V.; Araujo, D.; Ferreira, H.; Fonseca, C.; Palmeira, J.D. A walk on the wild side: Wild ungulates as potential reservoirs of multi-drug resistant bacteria and genes, including *Escherichia coli* harbouring CTX-M beta-lactamases. *Environ. Pollut.* **2022**, *306*, 119367. [[CrossRef](#)] [[PubMed](#)]
12. Tello, M.; Oejo, M.; Oporto, B.; Lavin, J.L.; Hurtado, A. Within-farm dynamics of ESBL-producing *Escherichia coli* in dairy cattle: Resistance profiles and molecular characterization by long-read whole-genome sequencing. *Front. Microbiol.* **2022**, *13*, 936843. [[CrossRef](#)] [[PubMed](#)]
13. Mengistu, T.S.; Garcias, B.; Castellanos, G.; Seminati, C.; Molina-Lopez, R.A.; Darwich, L. Occurrence of multidrug resistant Gram-negative bacteria and resistance genes in semi-aquatic wildlife—*Trachemys scripta*, *Neovison vison* and *Lutra lutra*—As sentinels of environmental health. *Sci. Total Environ.* **2022**, *830*, 154814. [[CrossRef](#)]
14. Aldea, I.; Gibello, A.; Hernandez, M.; Leekitcharoenphon, P.; Bortolaia, V.; Moreno, M.A. Clonal and plasmid-mediated flow of ESBL/AmpC genes in *Escherichia coli* in a commercial laying hen farm. *Vet. Microbiol.* **2022**, *270*, 109453. [[CrossRef](#)] [[PubMed](#)]
15. Elkenany, R.; Eltaysh, R.; Elsayed, M.; Abdel-Daim, M.; Shata, R. Characterization of multi-resistant Shigella species isolated from raw cow milk and milk products. *J. Vet. Med. Sci.* **2022**, *84*, 890–897. [[CrossRef](#)] [[PubMed](#)]
16. Bello Gonzalez, T.D.J.; Kant, A.; Dijkstra, Q.; Marcato, F.; van Reenen, K.; Veldman, K.T.; Brouwer, M.S.M. Changes in Fecal Carriage of Extended-Spectrum Beta-Lactamase Producing Enterobacteriales in Dutch Veal Calves by Clonal Spread of *Klebsiella pneumoniae*. *Front. Microbiol.* **2022**, *13*, 866674. [[CrossRef](#)]
17. Gelalcha, B.D.; Ensermu, D.B.; Agga, G.E.; Vancuren, M.; Gillespie, B.E.; D’Souza, D.H.; Okafor, C.C.; Kerro Deogo, O. Prevalence of Antimicrobial Resistant and Extended-Spectrum Beta-Lactamase-producing *Escherichia coli* in Dairy Cattle Farms in East Tennessee. *Foodborne Pathog. Dis.* **2022**, *19*, 408–416. [[CrossRef](#)]
18. Zontling, J.; Heckel, J.O.; Hotzel, H.; Fruth, A.; Pfeifer, Y.; Henning, K.; Kopp, P.; Mertens-Scholz, K.; Rietschel, W.; Pfeffer, M. Zoonotic bacteria in clinically healthy goats in petting zoo settings of zoological gardens in Germany. *Zoonoses Public Health* **2022**, *69*, 333–343. [[CrossRef](#)]
19. Karabasanavar, N.; Sivaraman, G.K.; S, P.S.; Nair, A.S.; Vijayan, A.; Rajan, V.; Girish, P.S. Non-diarrhoeic pigs as source of highly virulent and multidrug-resistant non-typhoidal *Salmonella*. *Braz. J. Microbiol.* **2022**, *53*, 1039–1049. [[CrossRef](#)]
20. Islam, M.M.; Farag, E.; Hassan, M.M.; Enan, K.A.; Mohammad Sabeel, K.V.; Alhaddad, M.M.; Smatti, M.K.; Al-Marri, A.M.; Al-Zeyara, A.A.; Al-Romaihi, H.; et al. Diversity of bacterial pathogens and their antimicrobial resistance profile among commensal rodents in Qatar. *Vet. Res. Commun.* **2022**, *46*, 487–498. [[CrossRef](#)]
21. Khawaskar, D.P.; Sinha, D.K.; Lalrinzuala, M.V.; Athira, V.; Kumar, M.; Chhakchhuak, L.; Mohanapriya, K.; Sophia, I.; Abhishek, Kumar, O.R.V.; et al. Pathotyping and antimicrobial susceptibility testing of *Escherichia coli* isolates from neonatal calves. *Vet. Res. Commun.* **2022**, *46*, 353–362. [[CrossRef](#)] [[PubMed](#)]
22. Haeili, M.; Salehzeinali, H.; Mirzaei, S.; Pishnian, Z.; Ahmadi, A. Molecular characterization of quinolone resistance and antimicrobial resistance profiles of *Klebsiella pneumoniae* and *Escherichia coli* isolated from human and broiler chickens. *Int. J. Environ. Health Res.* **2022**, *32*, 1382–1392. [[CrossRef](#)] [[PubMed](#)]
23. Aklilu, E.; Harun, A.; Singh, K.K.B. Molecular characterization of bla(NDM), bla(OXA-48), mcr-1 and bla(TEM-52) positive and concurrently carbapenem and colistin resistant and extended spectrum beta-lactamase producing *Escherichia coli* in chicken in Malaysia. *BMC Vet. Res.* **2022**, *18*, 190. [[CrossRef](#)]
24. Menck-Costa, M.F.; Baptista, A.A.S.; Gazal, L.E.S.; Justino, L.; Sanches, M.S.; de Souza, M.; Nishio, E.K.; Queiroz Dos Santos, B.; Cruz, V.D.; Berbert, J.V.M.; et al. High-Frequency Detection of fosA3 and bla (CTX-M-55) Genes in *Escherichia coli* From Longitudinal Monitoring in Broiler Chicken Farms. *Front. Microbiol.* **2022**, *13*, 846116. [[CrossRef](#)] [[PubMed](#)]
25. Ndukupi, J.G.; Gikunju, J.K.; Aboge, G.O.; Mwaniki, J.K.; Maina, J.N.; Mbaria, J.M. Molecular Characterization of ESBLs and QnrS Producers from Selected Enterobacteriaceae Strains Isolated from Commercial Poultry Production Systems in Kiambu County, Kenya. *Microbiol. Insights* **2022**, *15*, 11786361211063619. [[CrossRef](#)] [[PubMed](#)]

26. Su, X.; Yan, X.; Li, Y.; Zhang, D.; Li, L.; Geng, Y.; Su, F.; Yue, C.; Hou, R.; Liu, S. Identification of extended-spectrum beta-lactamase (CTX-M)-producing *Klebsiella pneumoniae* belonging to ST37, ST290, and ST2640 in captive giant pandas. *BMC Vet. Res.* **2022**, *18*, 186. [[CrossRef](#)] [[PubMed](#)]
27. Gruel, G.; Couvin, D.; Guyomard-Rabenirina, S.; Arlet, G.; Bambou, J.C.; Pot, M.; Roy, X.; Talarmin, A.; Tressieres, B.; Ferdinand, S.; et al. High Prevalence of bla (CTXM-1)/IncII-Igamma/ST3 Plasmids in Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* Isolates Collected from Domestic Animals in Guadeloupe (French West Indies). *Front. Microbiol.* **2022**, *13*, 882422. [[CrossRef](#)]
28. Mahmoud, S.F.; Fayez, M.; Swelum, A.A.; Alswat, A.S.; Alkafafy, M.; Alzahrani, O.M.; Alsunaini, S.J.; Almuslem, A.; Al Amer, A.S.; Yusuf, S. Genetic Diversity, Biofilm Formation, and Antibiotic Resistance of *Pseudomonas aeruginosa* Isolated from Cow, Camel, and Mare with Clinical Endometritis. *Vet. Sci.* **2022**, *9*, 239. [[CrossRef](#)]
29. Islam, M.S.; Sobur, M.A.; Rahman, S.; Ballah, F.M.; Ievy, S.; Siddique, M.P.; Rahman, M.; Kafi, M.A.; Rahman, M.T. Detection of bla(TEM), bla(CTX-M), bla(CMY), and bla(SHV) Genes Among Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* Isolated from Migratory Birds Travelling to Bangladesh. *Microb. Ecol.* **2022**, *83*, 942–950. [[CrossRef](#)]
30. Landolsi, S.; Selmi, R.; Hadjadj, L.; Ben Haj Yahia, A.; Ben Romdhane, K.; Messadi, L.; Rolain, J.M. First Report of Extended-Spectrum beta-Lactamase (bla(CTX-M1)) and Colistin Resistance Gene mcr-1 in *E. coli* of Lineage ST648 from Cockroaches in Tunisia. *Microbiol. Spectr.* **2022**, *10*, e0003621. [[CrossRef](#)]
31. Garcia-Fierro, R.; Drapeau, A.; Dazas, M.; Saras, E.; Rodrigues, C.; Brisse, S.; Madec, J.Y.; Haenni, M. Comparative phylogenomics of ESBL-, AmpC- and carbapenemase-producing *Klebsiella pneumoniae* originating from companion animals and humans. *J. Antimicrob. Chemother.* **2022**, *77*, 1263–1271. [[CrossRef](#)]
32. Belas, A.; Marques, C.; Menezes, J.; da Gama, L.T.; Cavaco-Silva, P.; Pomba, C. ESBL/pAmpC-Producing *Escherichia coli* Causing Urinary Tract Infections in Non-Related Companion Animals and Humans. *Antibiotics* **2022**, *11*, 559. [[CrossRef](#)] [[PubMed](#)]
33. Aworh, M.K.; Ekeng, E.; Nilsson, P.; Egyir, B.; Owusu-Nyantakyi, C.; Hendriksen, R.S. Extended-Spectrum ss-Lactamase-Producing *Escherichia coli* among Humans, Beef Cattle, and Abattoir Environments in Nigeria. *Front. Cell Infect. Microbiol.* **2022**, *12*, 869314. [[CrossRef](#)]
34. Nuesch-Inderbinen, M.; Hanni, C.; Zurfluh, K.; Hartnack, S.; Stephan, R. Antimicrobial resistance profiles of *Escherichia coli* and prevalence of extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in calves from organic and conventional dairy farms in Switzerland. *Microbiologyopen* **2022**, *11*, e1269. [[CrossRef](#)]
35. Samir, A.; Abdel-Moein, K.A.; Zaher, H.M. The Public Health Burden of Virulent Extended-Spectrum Beta-Lactamase-Producing *Klebsiella pneumoniae* Strains Isolated from Diseased Horses. *Vector-Borne Zoonotic Dis.* **2022**, *22*, 217–224. [[CrossRef](#)]
36. Loucif, L.; Chelaghma, W.; Cherak, Z.; Bendjama, E.; Beroual, F.; Rolain, J.M. Detection of NDM-5 and MCR-1 antibiotic resistance encoding genes in Enterobacterales in long-distance migratory bird species *Ciconia ciconia*, Algeria. *Sci. Total Environ.* **2022**, *814*, 152861. [[CrossRef](#)] [[PubMed](#)]
37. Benavides, J.A.; Godreuil, S.; Opazo-Capurro, A.; Mahamat, O.O.; Falcon, N.; Oravcova, K.; Streicker, D.G.; Shiva, C. Long-term maintenance of multidrug-resistant *Escherichia coli* carried by vampire bats and shared with livestock in Peru. *Sci. Total Environ.* **2022**, *810*, 152045. [[CrossRef](#)]
38. Trongjit, S.; Assavacheep, P.; Samngamnim, S.; My, T.H.; An, V.T.T.; Simjee, S.; Chuanchuen, R. Plasmid-mediated colistin resistance and ESBL production in *Escherichia coli* from clinically healthy and sick pigs. *Sci. Rep.* **2022**, *12*, 2466. [[CrossRef](#)] [[PubMed](#)]
39. Dallenne, C.; Da Costa, A.; Decre, D.; Favier, C.; Arlet, G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. *J. Antimicrob. Chemother.* **2010**, *65*, 490–495. [[CrossRef](#)]
40. Randall, L.P.; Cooles, S.W.; Osborn, M.K.; Piddock, L.J.; Woodward, M.J. Antibiotic resistance genes, integrons and multiple antibiotic resistance in thirty-five serotypes of *Salmonella enterica* isolated from humans and animals in the UK. *J. Antimicrob. Chemother.* **2004**, *53*, 208–216. [[CrossRef](#)]
41. Strauss, L.M.; Dahms, C.; Becker, K.; Kramer, A.; Kaase, M.; Mellmann, A. Development and evaluation of a novel universal beta-lactamase gene subtyping assay for blaSHV, blaTEM and blaCTX-M using clinical and livestock-associated *Escherichia coli*. *J. Antimicrob. Chemother.* **2015**, *70*, 710–715. [[CrossRef](#)]
42. Gootz, T.D.; Lescoe, M.K.; Dib-Hajj, F.; Dougherty, B.A.; He, W.; Della-Latta, P.; Huard, R.C. Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from *Klebsiella* strains isolated in a New York City hospital. *Antimicrob. Agents Chemother.* **2009**, *53*, 1998–2004. [[CrossRef](#)]
43. Bhattacharjee, A.; Sen, M.R.; Anupurba, S.; Prakash, P.; Nath, G. Detection of OXA-2 group extended-spectrum-beta-lactamase-producing clinical isolates of *Escherichia coli* from India. *J. Antimicrob. Chemother.* **2007**, *60*, 703–704. [[CrossRef](#)]
44. Christophy, R.; Osman, M.; Mallat, H.; Achkar, M.; Ziedeh, A.; Moukaddem, W.; Dabboussi, F.; Hamze, M. Prevalence, antibiotic susceptibility and characterization of antibiotic resistant genes among carbapenem-resistant Gram-negative bacilli and yeast in intestinal flora of cancer patients in North Lebanon. *J. Infect. Public Health* **2017**, *10*, 716–720. [[CrossRef](#)]
45. Grobner, S.; Linke, D.; Schutz, W.; Fladerer, C.; Madlung, J.; Autenrieth, I.B.; Witte, W.; Pfeifer, Y. Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* isolates at the university hospital of Tubingen, Germany. *J. Med. Microbiol.* **2009**, *58*, 912–922. [[CrossRef](#)]
46. Ly, T.D.A.; Hadjadj, L.; Hoang, V.T.; Louni, M.; Dao, T.L.; Badiaga, S.; Tissot-Dupont, H.; Raoult, D.; Rolain, J.M.; Gautret, P. Low prevalence of resistance genes in sheltered homeless population in Marseille, France, 2014–2018. *Infect. Drug Resist.* **2019**, *12*, 1139–1151. [[CrossRef](#)] [[PubMed](#)]

47. Hosu, M.C.; Vasaikar, S.D.; Okuthe, G.E.; Apalata, T. Detection of extended spectrum beta-lactamase genes in *Pseudomonas aeruginosa* isolated from patients in rural Eastern Cape Province, South Africa. *Sci. Rep.* **2021**, *11*, 7110. [[CrossRef](#)]
48. Pitout, J.D.; Thomson, K.S.; Hanson, N.D.; Ehrhardt, A.F.; Moland, E.S.; Sanders, C.C. beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in *Klebsiella pneumoniae*, *Escherichia coli*, and *Proteus mirabilis* isolates recovered in South Africa. *Antimicrob. Agents Chemother.* **1998**, *42*, 1350–1354. [[CrossRef](#)]
49. Fang, H.; Ataker, F.; Hedin, G.; Dornbusch, K. Molecular epidemiology of extended-spectrum beta-lactamases among *Escherichia coli* isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. *J. Clin. Microbiol.* **2008**, *46*, 707–712. [[CrossRef](#)] [[PubMed](#)]
50. Hasman, H.; Mevius, D.; Veldman, K.; Olesen, I.; Aarestrup, F.M. Beta-Lactamases among extended-spectrum beta-lactamase (ESBL)-resistant *Salmonella* from poultry, poultry products and human patients in The Netherlands. *J. Antimicrob. Chemother.* **2005**, *56*, 115–121. [[CrossRef](#)] [[PubMed](#)]
51. Ali, T.; Rahman, S.U.; Zhang, L.; Shahid, M.; Han, D.; Gao, J.; Zhang, S.; Ruegg, P.L.; Saddique, U.; Han, B. Characteristics and genetic diversity of multi-drug resistant extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* isolated from bovine mastitis. *Oncotarget* **2017**, *8*, 90144–90163. [[CrossRef](#)] [[PubMed](#)]
52. Weill, F.X.; Demartin, M.; Tande, D.; Espie, E.; Rakotoarivony, I.; Grimont, P.A. SHV-12-like extended-spectrum-beta-lactamase-producing strains of *Salmonella enterica* serotypes Babelsberg and Enteritidis isolated in France among infants adopted from Mali. *J. Clin. Microbiol.* **2004**, *42*, 2432–2437. [[CrossRef](#)] [[PubMed](#)]
53. Colom, K.; Perez, J.; Alonso, R.; Fernandez-Aranguiz, A.; Larino, E.; Cisterna, R. Simple and reliable multiplex PCR assay for detection of bla_{TEM}, bla_(SHV) and bla_{OXA-1} genes in Enterobacteriaceae. *FEMS Microbiol. Lett.* **2003**, *223*, 147–151. [[CrossRef](#)]
54. Rayamajhi, N.; Kang, S.G.; Lee, D.Y.; Kang, M.L.; Lee, S.I.; Park, K.Y.; Lee, H.S.; Yoo, H.S. Characterization of TEM-, SHV- and AmpC-type beta-lactamases from cephalosporin-resistant Enterobacteriaceae isolated from swine. *Int. J. Food Microbiol.* **2008**, *124*, 183–187. [[CrossRef](#)] [[PubMed](#)]
55. Lob, S.H.; Kazmierczak, K.M.; Badal, R.E.; Hackel, M.A.; Bouchillon, S.K.; Biedenbach, D.J.; Sahm, D.F. Trends in susceptibility of *Escherichia coli* from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. *Antimicrob. Agents Chemother.* **2015**, *59*, 3606–3610. [[CrossRef](#)]
56. El-Shazly, S.; Dashti, A.; Vali, L.; Bolaris, M.; Ibrahim, A.S. Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of *Acinetobacter baumannii*. *Int. J. Infect. Dis.* **2015**, *41*, 42–49. [[CrossRef](#)]
57. Van, T.T.; Chin, J.; Chapman, T.; Tran, L.T.; Coloe, P.J. Safety of raw meat and shellfish in Vietnam: An analysis of *Escherichia coli* isolations for antibiotic resistance and virulence genes. *Int. J. Food Microbiol.* **2008**, *124*, 217–223. [[CrossRef](#)]
58. Archambault, M.; Petrov, P.; Hendriksen, R.S.; Asseva, G.; Bangtrakulnonth, A.; Hasman, H.; Aarestrup, F.M. Molecular characterization and occurrence of extended-spectrum beta-lactamase resistance genes among *Salmonella enterica* serovar Corvallis from Thailand, Bulgaria, and Denmark. *Microb. Drug Resist.* **2006**, *12*, 192–198. [[CrossRef](#)]
59. Ahmed, O.I.; El-Hady, S.A.; Ahmed, T.M.; Ahmed, I.Z. Detection of bla_{SHV} and bla_{CTX-M} genes in ESBL producing *Klebsiella pneumoniae* isolated from Egyptian patients with suspected nosocomial infections. *Egypt. J. Med. Hum. Genet.* **2013**, *14*, 277–283. [[CrossRef](#)]
60. Gundran, R.S.; Cardenio, P.A.; Villanueva, M.A.; Sison, F.B.; Benigno, C.C.; Kreasukon, K.; Pichpol, D.; Punyapornwithaya, V. Prevalence and distribution of bla_(CTX-M), bla_(SHV), bla_(TEM) genes in extended-spectrum beta-lactamase-producing *E. coli* isolates from broiler farms in the Philippines. *BMC Vet. Res.* **2019**, *15*, 227. [[CrossRef](#)]
61. Batchelor, M.; Hopkins, K.; Threlfall, E.J.; Clifton-Hadley, F.A.; Stallwood, A.D.; Davies, R.H.; Liebana, E. Bla_(CTX-M) genes in clinical *Salmonella* isolates recovered from humans in England and Wales from 1992 to 2003. *Antimicrob. Agents Chemother.* **2005**, *49*, 1319–1322. [[CrossRef](#)]
62. Edelstein, M.; Pimkin, M.; Palagin, I.; Edelstein, I.; Stratchounski, L. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in Russian hospitals. *Antimicrob. Agents Chemother.* **2003**, *47*, 3724–3732. [[CrossRef](#)] [[PubMed](#)]
63. Horton, R.A.; Randall, L.P.; Snary, E.L.; Cockrem, H.; Lotz, S.; Wearing, H.; Duncan, D.; Rabie, A.; McLaren, I.; Watson, E.; et al. Fecal carriage and shedding density of CTX-M extended-spectrum beta-lactamase-producing *Escherichia coli* in cattle, chickens, and pigs: Implications for environmental contamination and food production. *Appl. Environ. Microbiol.* **2011**, *77*, 3715–3719. [[CrossRef](#)] [[PubMed](#)]
64. Woodford, N.; Fagan, E.J.; Ellington, M.J. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases. *J. Antimicrob. Chemother.* **2006**, *57*, 154–155. [[CrossRef](#)] [[PubMed](#)]
65. Pfeifer, Y.; Matten, J.; Rabsch, W. *Salmonella enterica* serovar Typhi with CTX-M beta-lactamase, Germany. *Emerg. Infect. Dis.* **2009**, *15*, 1533–1535. [[CrossRef](#)]
66. Wetzker, W.; Pfeifer, Y.; Wolke, S.; Haselbeck, A.; Leistner, R.; Kola, A.; Gastmeier, P.; Salm, F. Extended-Spectrum Beta-Lactamase (ESBL)-Producing *Escherichia coli* Isolated from Flies in the Urban Center of Berlin, Germany. *Int. J. Environ. Res. Public Health* **2019**, *16*, 1530. [[CrossRef](#)]
67. Carattoli, A. Animal reservoirs for extended spectrum beta-lactamase producers. *Clin. Microbiol. Infect.* **2008**, *14* (Suppl. S1), 117–123. [[CrossRef](#)]
68. Dantas Palmeira, J.; Ferreira, H.M.N. Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in cattle production—A threat around the world. *Heliyon* **2020**, *6*, e03206. [[CrossRef](#)]

69. Mesbah Zekar, F.; Granier, S.A.; Marault, M.; Yaici, L.; Gassilloud, B.; Manceau, C.; Touati, A.; Millemann, Y. From Farms to Markets: Gram-Negative Bacteria Resistant to Third-Generation Cephalosporins in Fruits and Vegetables in a Region of North Africa. *Front. Microbiol.* **2017**, *8*, 1569. [[CrossRef](#)]
70. De Boeck, H.; Miwanda, B.; Lunguya-Metila, O.; Muyembe-Tamfum, J.J.; Stobberingh, E.; Glupczynski, Y.; Jacobs, J. ESBL-positive Enterobacteria isolates in drinking water. *Emerg. Infect. Dis.* **2012**, *18*, 1019–1020. [[CrossRef](#)]
71. World Health Organization. *WHO Integrated Global Surveillance on ESBL-Producing E. coli Using a “One Health” Approach: Implementation and Opportunities*; World Health Organization: Geneva, Switzerland, 2021.
72. Bradford, P.A. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. *Clin. Microbiol. Rev.* **2001**, *14*, 933–951. [[CrossRef](#)] [[PubMed](#)]
73. Brazelton de Cardenas, J.N.; Garner, C.D.; Su, Y.; Tang, L.; Hayden, R.T. Comparative Evaluation of Assays for Broad Detection of Molecular Resistance Mechanisms in Enterobacterales Isolates. *J. Clin. Microbiol.* **2021**, *59*, e0103321. [[CrossRef](#)] [[PubMed](#)]
74. Wang, J.; Stephan, R.; Karczmarczyk, M.; Yan, Q.; Hachler, H.; Fanning, S. Molecular characterization of bla ESBL-harboring conjugative plasmids identified in multi-drug resistant *Escherichia coli* isolated from food-producing animals and healthy humans. *Front. Microbiol.* **2013**, *4*, 188. [[CrossRef](#)] [[PubMed](#)]
75. Wang, J.; Stephan, R.; Power, K.; Yan, Q.; Hachler, H.; Fanning, S. Nucleotide sequences of 16 transmissible plasmids identified in nine multidrug-resistant *Escherichia coli* isolates expressing an ESBL phenotype isolated from food-producing animals and healthy humans. *J. Antimicrob. Chemother.* **2014**, *69*, 2658–2668. [[CrossRef](#)]
76. Anes, J.; Nguyen, S.V.; Eshwar, A.K.; McCabe, E.; Macori, G.; Hurley, D.; Lehner, A.; Fanning, S. Molecular characterisation of multi-drug resistant *Escherichia coli* of bovine origin. *Vet. Microbiol.* **2020**, *242*, 108566. [[CrossRef](#)]
77. Saidani, M.; Messadi, L.; Mefteh, J.; Chaouechi, A.; Soudani, A.; Selmi, R.; Daaloul-Jedidi, M.; Ben Chehida, F.; Mamlouk, A.; Jemli, M.H.; et al. Various Inc-type plasmids and lineages of *Escherichia coli* and *Klebsiella pneumoniae* spreading bla(CTX-M-15), bla(CTX-M-1) and mcr-1 genes in camels in Tunisia. *J. Glob. Antimicrob. Resist.* **2019**, *19*, 280–283. [[CrossRef](#)]
78. Pepin-Puget, L.; El Garch, F.; Bertrand, X.; Valot, B.; Hocquet, D. Genome analysis of enterobacteriaceae with non-wild type susceptibility to third-generation cephalosporins recovered from diseased dogs and cats in Europe. *Vet. Microbiol.* **2020**, *242*, 108601. [[CrossRef](#)]
79. Rozwandowicz, M.; Brouwer, M.S.M.; Fischer, J.; Wagenaar, J.A.; Gonzalez-Zorn, B.; Guerra, B.; Mevius, D.J.; Hordijk, J. Plasmids carrying antimicrobial resistance genes in *Enterobacteriaceae*. *J. Antimicrob. Chemother.* **2018**, *73*, 1121–1137. [[CrossRef](#)]
80. Wiegand, I.; Geiss, H.K.; Mack, D.; Sturenburg, E.; Seifert, H. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. *J. Clin. Microbiol.* **2007**, *45*, 1167–1174. [[CrossRef](#)]
81. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* **2021**, *372*, n71. [[CrossRef](#)]
82. University of Alabama. A Research Guide for Systematic Literature Reviews. *University Libraries*. Available online: <https://guides.lib.ua.edu/c.php?g=1135040&p=8286355> (accessed on 24 May 2022).

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.